Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?
Status:
Unknown status
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major
clinical problems among antipsychotic-treated patients. Especially two of the most
efficacious antipsychotics, clozapine and olanzapine, cause weight gain and metabolic
disturbances and can rarely be replaced by other drugs due to the effectiveness of the
compounds. Glucagon-like peptide 1 (GLP-1) has improved glycemic control among patients with
type 2 diabetes. The study will investigate whether the beneficial effects of GLP-1 analogues
on glycemic control in type 2 diabetic patients, can be extended to a population of
non-diabetic, dysglycemic psychiatric patients, receiving antipsychotic medical treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Psychiatric Centre Rigshospitalet
Collaborators:
University Hospital, Gentofte, Copenhagen University of Cambridge